Endourology and StonesEarly Application of Permanent Metallic Mesh Stent in Substitution for Temporary Polymeric Ureteral Stent Reduces Unnecessary Ureteral Procedures in Patients With Malignant Ureteral Obstruction
Section snippets
Patients and Methods
Patients who underwent ureteral metallic stent (UVENTA ureteral stent, TaeWoong Medical, South Korea) placement for a previously placed PDJ stent due to extrinsic MUO were included in the analysis. The UVENTA is a segmental ureteral stent made of double-layered, shape-memory strands of nickel-titanium alloy that are self-expandable, and a polytetrafluoroethylene cover between the two layers of metallic mesh is designed to prevent stent migration and urothelium anchoring. Replacement of the
Results
The median follow-up duration was 240 days after metallic mesh stent placement and 378 days after PDJ ureteral stent placement. The primary diseases that induced extrinsic MUO and the reasons for PDJ stent placement failure are shown in Figure 1. The patient baseline characteristics are outlined in Table 1.
The initial technical failure rate of metallic mesh stent placement was 0% (0/40). No procedure-related complications were reported, and no additional procedure was performed due to
Comments
PDJ ureteral stent placement is commonly performed during the early stage of extrinsic MUO for renal preservation and symptom relief; however, many studies have reported unsatisfactory success rates and various complications.16, 17, 18, 19, 20 Accordingly, various metal materials for ureteral stents have been described to achieve long-lasting ureteric patency and decrease the rate of complications due to PDJ ureteral stenting.
Wallstents (Schneider, Zürich, Switzerland) are made from a
Conclusion
The data presented here identified the duration of previous PDJ ureteral stenting as an independent prognostic factor for UVENTA stenting failure-free survival. Our findings indicate that UVENTA ureteral stenting can be a good option for patients who have had a PDJ ureteral stent for a relatively short time.
References (30)
- et al.
Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences?
Urology
(2004) - et al.
Malignant ureteral obstruction: outcomes after intervention. Have things changed?
J Urol
(2007) - et al.
Palliative care of malignant ureteral obstruction with polytetrafluoroethylene membrane-covered self-expandable metallic stents: initial experience
Korean J Urol
(2012) - et al.
Evaluation of a chronic indwelling prototype mesh ureteral stent in a porcine model
Urology
(2000) - et al.
The management of malignant ureteral obstruction treated with ureteral stents
J Urol
(2005) - et al.
15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents
J Urol
(2004) - et al.
High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: experience at 2 institutions
J Urol
(1989) Ureteral stents. Indications, variations, and complications
Urol Clin North Am
(1988)- et al.
Nickel-titanium shape memory alloy Memokath 051 ureteral stent for managing long-term ureteral obstruction: 4-year experience
J Urol
(2001) - et al.
Metal ureteral stent for benign and malignant ureteral obstruction
J Urol
(2011)
Metallic stent in the treatment of ureteral obstruction: experience of single institute
J Chin Med Assoc
Anatomic, functional, and pathologic changes from internal ureteral stent placement
Urology
Stent-change therapy in advanced malignancies with ureteral obstruction
J Endourol
Urologic emergencies in the cancer patient
Semin Oncol
Self-expanding metal stents for palliative treatment of malignant ureteral obstruction
AJR Am J Roentgenol
Cited by (17)
Innovations in Ureteral Stent Technology
2019, Urologic Clinics of North AmericaCitation Excerpt :Caution should be used with current-generation metal-mesh stents because their long-term consequences on ureteric physiology are not fully characterized. Changes reported to date include edema, fibrosis, and ureteric wall thickening.42 The Memokath 051 (PNN Medical, Kvistgaard, Denmark) is another expandable metallic stent designed specifically for the ureter.
Metallic Ureteric Stents in Malignant Ureteric Obstruction: A Systematic Review
2018, UrologyCitation Excerpt :They report 100% stent patency at median follow-up of 8 months, although de novo ureteric obstruction developed in 9 cases to give an overall success rate of 77.5%. Cox regression analysis for predictors of failure demonstrated significance for duration of previous DJS placement (although the authors note this could possibly be explained by disease progression).30 Two included studies contained unextractable data.
The effectiveness of ureteric metal stents in malignant ureteric obstructions: A systematic review
2017, Arab Journal of UrologyCitation Excerpt :Complications include haematuria, flank or abdominal pain, encrustation, UTIs, sepsis, and VUR. High rates of migration, decreased peristalsis of the ureter and relative obstruction, the possibility of loss of patency due to the extrinsic pressure, and the need for frequent replacements, are some of the disadvantages [1,2]. Patients with advanced malignant disease have a short life-expectancy and the quality of life should be taken into consideration when establishing a management plan.
In vitro and in vivo corrosion and histocompatibility of pure Mg and a Mg-6Zn alloy as urinary implants in rat model
2016, Materials Science and Engineering CStents for malignant ureteral obstruction
2016, Asian Journal of UrologyManagement of single double-J stent failure in malignant ureteral obstruction: tandem ureteral stenting with less frequent stent exchange
2023, Diagnostic and Interventional Radiology
Financial Disclosure: The authors declare that they have no relevant financial interests.